Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of Fovista plus Lucentis versus Lucentis alone in neovascular age-related macular degeneration
2013-003017-18Phase 3Terminated
- Sponsor
- IVERIC bio
- Start
- Sep 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration, subfoveal choroidal neovascularization (CNV) and age-related macular degeneration (AMD) comparing Fovista + Lucentis with Lucentis monotherapy (2 arms). Primary endpoint: Mean change in visual acuity from baseline at Month 12. Started Sep 2013; status: terminated.
02
Drugs
pegpleranibranibizumab
03
Conditions
exudative macular degenerationsubfoveal choroidal neovascularization (CNV)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2013-003017-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003017-18.